If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 161 - 170 of 279
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Objective
Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa
Protocol No
DERM-ELILILLY-I7P-MC-DSAF
Categories
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
Objective
Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy
Protocol No
NEPH-ALEXION-ALXN1210-IGAN-320
Categories
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer,
Other Skin,
Bladder,
Colorectal,
Cervix,
Other Gynecologic,
Breast Cancers,
Esophagus,
Prostate,
Larynx,
Other Gastrointestinal,
Esophagus,
Gynecologic Cancers,
Other Respiratory,
Melanoma, Skin,
Prostate and Urologic Cancers,
Pancreas/Liver,
Eye/Orbital Cancers,
Thoracic Cancers,
Lip, Oral Cavity and Pharynx,
Head and Neck Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Skin Cancers,
Brain and Spine Cancers
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (RPS) (EORTC-1809: STRASS 2)
Objective
A randomized study investigating preoperative chemotherapy followed by surgery versus surgery alone in patients with high risk retroperitoneal sarcoma (STRASS2)
Protocol No
ECOG-EA7211
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Objective
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Categories
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Objective
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Protocol No
GOG-3082-ACRIVON-ACR-368-201
Categories
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) with Anti-Angiogenesis and Chemotherapy in Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Objective
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL)
Protocol No
HCRN-GI18-333-SEQUEL
Categories
Combination Post-Transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
Objective
The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No
IIT-MOHAN-E-MAT
Categories
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Objective
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Protocol No
ECOG-EA3191
Categories
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer,
Colorectal,
Gynecologic Cancers,
Esophagus,
Other Urologic,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Esophagus,
Skin Cancers,
Stomach,
Prostate and Urologic Cancers,
Pancreas/Liver,
Breast Cancers,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Lung,
Thoracic Cancers